ERBB2 and neoplasm: Due to the fact that these triple negative (ERα-/PgR-/Her-2) cancer cells are considered to be very aggressive and since some commonly used chemotherapeutics like Herceptin (HER-2 targeting) lack activity on these kinds of cells, alternative approaches are necessary to affect such tumor types.